SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla surges on acquiring brand name, trademark rights for Vysov

17 Dec 2019 Evaluate

Cipla is currently trading at Rs. 462.65, up by 4.05 points or 0.88% from its previous closing of Rs. 458.60 on the BSE.

The scrip opened at Rs. 463.70 and has touched a high and low of Rs. 466.00 and Rs. 460.55 respectively. So far 17250 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 585.50 on 27-May-2019 and a 52 week low of Rs. 389.55 on 11-Oct-2019.

Last one week high and low of the scrip stood at Rs. 466.00 and Rs. 446.85 respectively. The current market cap of the company is Rs. 37304.15 crore.

The promoters holding in the company stood at 36.68%, while Institutions and Non-Institutions held 41.79% and 21.53% respectively.

Cipla has acquired the brand name and trademark rights for Vysov & Vysov M (Vildagliptin plus Metformin) of the anti-diabetic drug, Vildagliptin for the Indian market. The company has been co-marketing Vildagliptin in agreement with Novartis under brand names Vysov & Vysov M and has witnessed a strong uptake for the product in India for the last couple of years. It is currently available across the country. The current market size of Vildagliptin is Rs 818 crore as per IQVIA MAT Nov 2019 in India.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla Share Price

1232.90 4.00 (0.33%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×